In the rapidly expanding field of microbiome therapeutics, the interaction between beneficial bacteria and complex carbohydrates is the cornerstone of gut health. CD BioGlyco presents the glycan-related probiotic modification service, a high-end technical offering within our Synthetic Biology-based Glycan Modification Platform. We recognize that the efficacy of probiotics is often limited by their ability to survive the gastrointestinal passage and colonize the mucosal layer. By modifying the surface glycans of probiotic strains or engineering their metabolic pathways to utilize specific prebiotic fibers, we enhance their persistence, adhesion, and therapeutic output. Our service utilizes precision synthetic biology to "tailor" the glycan-probiotic interface, ensuring that your beneficial microbial candidates are equipped with the molecular tools necessary to outcompete pathogens and provide sustained health benefits.
Core Technologies
CD BioGlyco leverages state-of-the-art biological engineering to optimize probiotic-glycan interactions:
Metabolic Glycan Engineering
Introducing biosynthetic pathways into probiotic chassis to produce non-natural or rare surface glycans that mimic host mucosal patterns for enhanced immune evasion and colonization.
HMO Utilization Pathway Engineering
Equipping diverse probiotic species with specialized transporters and glycosidases to specifically ferment human milk oligosaccharides (HMOs), providing a competitive advantage in infant and adult gut environments.
Surface Display of Glycan-Binding Proteins (GBPs)
Engineering the probiotic cell wall to express specific lectins or carbohydrate-binding modules that target localized glycan structures in the intestinal epithelium.
Precision Prebiotic Pairing
Developing customized glycan structures that are exclusively utilized by the modified probiotic strain (an orthogonal "synbiotic" approach) to ensure selective expansion of the therapeutic microbe.
Glyco-Editing
Precisely deleting or inserting genes involved in exopolysaccharide (EPS) production to modulate the probiotic's biofilm formation and stress resistance.
Synchronizing Microbial Life with Glycan Intelligence for Superior Gut Health.
Our service scope for glycan-related probiotic modification covers the full spectrum of microbiome-targeted innovation. We specialize in the engineering of cross-feeding networks, where modified probiotics are designed to release specific glycan fragments that support the growth of other beneficial indigenous microbes, such as butyrate-producers. This holistic approach moves beyond single-strain supplements toward "ecosystem-level" microbiome engineering. We also offer exopolysaccharide (EPS) tailoring, modifying the chemical composition and branching of the glycans secreted by probiotics to improve their immunomodulatory properties and their ability to protect the gut barrier.
CD BioGlyco provides extensive expertise in HMO-targeted probiotics, engineering strains that can efficiently utilize 2'-fucosyllactose (2'-FL) and other complex milk sugars for pediatric and geriatric health applications. Our service includes the development of glycan-responsive probiotics, which can be engineered to express therapeutic proteins only when they detect specific carbohydrate markers of inflammation or pathogen presence in the gut. We support a wide range of microbial chassis, including Bifidobacterium, Lactobacillus, and Akkermansia species. Whether you are developing a "smart" probiotic for IBD management or an enhanced synbiotic for metabolic health, our glycan modification service provides the molecular precision to ensure your product survives, thrives, and delivers its therapeutic payload exactly where it is needed. With a focus on stability, scalability, and safety, we help you bridge the gap between basic probiotic research and next-generation bioscaffolds.
Workflow
Microbial Chassis Characterization
We begin with a detailed systems-level analysis of your probiotic strain. This includes whole-genome sequencing and annotation to map native carbohydrate-active enzymes (CAZymes), transporters, and regulatory elements. Concurrent glycomic profiling, using techniques like LC-MS/MS, characterizes the strain's surface polysaccharides and capsular structures. This dual-omics baseline identifies existing glycan utilization capabilities and reveals targets for engineering enhanced host-microbe or diet-microbe interactions.
Strategic Engineering Design
Leveraging insights from characterization, we employ genome-scale metabolic modeling and in silico pathway analysis to design precise genetic interventions. Strategies may include the knockout of competing pathways, the heterologous expression of specific glycosidases (e.g., sialidases, fucosidases) or glycosyltransferases, and the modulation of glycocalyx biosynthesis genes. The design objective is to reprogram the strain's glycan metabolism and surface architecture to achieve a defined functional outcome, such as improved mucosal adhesion, prebiotic fiber utilization, or immunomodulatory signaling.
Synthetic Biology Implementation
The designed genetic modules are stably integrated into the probiotic chromosome using high-efficiency, marker-free editing systems like recombinase-mediated cassette exchange. We prioritize genomic integration over plasmid-based systems to ensure long-term genetic stability and functionality without antibiotic selection, which is critical for therapeutic applications. All constructs are codon-optimized and placed under regulated promoters suitable for the anaerobic gastrointestinal environment.
Phenotypic Validation
Engineered strains undergo rigorous in vitro phenotypic screening. We utilize anaerobic fermenters to quantitatively assess growth kinetics on target prebiotic fibers (e.g., HMOs, GOS, arabinoxylans). Adhesion capacity is measured using mucin-coated surfaces or cultured intestinal epithelial cell monolayers. Key performance indicators, including glycan consumption rates, metabolic byproduct profiles, and competitive growth advantages, are benchmarked against the wild-type strain.
Simulated GI Passage Testing
The most promising candidates are subjected to validated, multi-compartmental simulated gastrointestinal (GI) models that replicate stomach acidity, bile salt concentrations, and colonic conditions. We measure and compare the survival rates, metabolic activity, and functional stability (e.g., retained enzymatic activity) of engineered versus wild-type strains. This step is critical to confirm that the glycan-modifying phenotype provides a tangible fitness benefit for in vivo application.
Multi-Omics Reporting
A comprehensive final report delivers vertical data integration. It includes comparative transcriptomic (RNA-seq) and metabolomic (untargeted MS) analyses of the engineered strain under relevant conditions. This data verifies the intended on-target effects (e.g., upregulation of the introduced pathway), assesses potential metabolic burdens or compensatory changes, and confirms the absence of significant off-target effects, providing a complete molecular validation of the engineering success.
Publication Data
Journal: Scientific Reports
DOI: 10.1038/am.2017.241
Published: 2024
IF: 3.9
Results: In this study, the authors developed a novel glycoside hydrolase (GH) enzyme simulator to model the degradation of HMOs and mucin-type O-glycans. They used this in silico tool to analyze the enzymatic profiles of over 8,000 bacterial species, predicting their potential to digest these dietary and host glycans. The simulations confirmed the superior capability of beneficial Bifidobacteria but revealed, surprisingly, that the pathogen Clostridium perfringens possesses a similarly diverse GH apparatus, suggesting a potential for opportunistic colonization in the infant gut. By calculating potential energy scores from simulated digestions, the study ranked bacterial species based on their predicted metabolic efficiency. Furthermore, comparative enzyme profile analysis was used to infer potential symbiotic or competitive interactions between gut microbes. This computational approach provides a framework for understanding how glycoside hydrolase equipment influences microbial ecology and pathogenicity in the gut environment.
Applications
Metabolic Disease Management
We engineer probiotic strains to specifically target and ferment dietary fibers that are underutilized in metabolic disorders. This is achieved by introducing novel glycan-active enzymes that enable the probiotic to convert complex plant-derived glycans (such as resistant starches or arabinoxylans) into beneficial short-chain fatty acids (SCFAs), notably butyrate and propionate. These SCFAs are known to improve host insulin sensitivity, regulate lipid metabolism, and reduce systemic inflammation, offering a direct, microbiome-mediated strategy for managing obesity, type 2 diabetes, and metabolic syndrome.
IBD and IBS Therapeutics Development
For inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), we design probiotics with modified surface glycan structures. These engineered glycocalyx components are tailored to enhance specific anti-inflammatory signaling (e.g., via interactions with host immune cell receptors like Siglecs) and to promote mucosal barrier repair by stimulating goblet cell differentiation and mucin production. The goal is to create next-generation biotherapeutics that no longer merely survive in the inflamed gut but actively restore immune homeostasis and epithelial integrity in patients with a compromised intestinal barrier.
Anti-Pathogen Defenses
We develop probiotic biocontrol agents engineered to express and secrete high-affinity glycan-based decoys. These soluble, multivalent carbohydrate structures are designed to mimic host cell surface receptors, such as the glycans targeted by bacterial toxins. By preemptively binding and neutralizing exotoxins (e.g., from Clostridioides difficile or enterotoxigenic E. coli) within the intestinal lumen, these probiotics act as molecular sponges. This strategy directly counteracts pathogen virulence, alleviates disease symptoms, and supports microbiota restoration without the use of broad-spectrum antibiotics.
Oral Health Innovation
We engineer commensal oral bacteria, such as selected strains of Streptococcus or Lactobacillus, to express modified surface adhesins with enhanced affinity for specific receptors in the salivary pellicle. This promotes the competitive exclusion of cariogenic pathogens like Streptococcus mutans by saturating binding sites and forming a protective, early-colonizing biofilm. Additionally, strains can be designed to secrete specific glycans that interfere with the cohesion of pathogenic biofilms. This approach aims to rebalance the oral microbiome, prevent plaque formation, and reduce the risk of dental caries through targeted microbial interference.
Advantages
Orthogonal Prebiotic Utilization
We engineer probiotics to eat "exclusive" glycans, preventing the expansion of opportunistic pathogens that might otherwise thrive on standard prebiotics.
Improved GI Survival
Tailored exopolysaccharide coatings act as a biological shield, significantly increasing recovery rates after exposure to harsh stomach acids and bile.
Targeted HMO Fermentation
CD BioGlyco-modified strains possess superior kinetics for utilizing complex human milk sugars, making them ideal candidates for the infant formula industry.
Optimized Biofilm Architecture
By editing glycan-synthesis genes, we create probiotics that form stronger, more protective biofilms to physically exclude enteric pathogens.
Frequently Asked Questions
Customer Review
"The in vitro and ex vivo adhesion data for our neuro-active probiotic strains, post-modification by CD BioGlyco, were outstanding. Their deep expertise in host mucosal glycan biology allowed them to precisely tailor the bacterial surface, resulting in a quantifiable 5 to 10-fold increase in adherence to relevant intestinal models. Their work is clearly world-class in this specialized niche."
– Manager, Gut-Brain Axis Research Program
"Scale-up from the shake flask to a manufacturing-ready process is always a major hurdle. We were initially concerned, but the glycan-engineered strains delivered by CD BioGlyco demonstrated exceptional genetic and phenotypic robustness. They maintained their precise glycan-utilization profile and growth characteristics seamlessly through pilot fermentations in our 1000L tanks, which is a testament to stable, well-integrated engineering."
– Dr. E.N., Head of Bioprocess Development, Fermentation Sciences
"CD BioGlyco designed a complete synbiotic system for us, pairing a novel, structurally defined fiber with a probiotic genetically optimized to consume it. This orthogonal pair created a virtuous cycle in the gut. The initial pilot study results were excellent, showing a significant, sustained increase in the desired beneficial microbial metabolites and a corresponding positive shift in host metabolic markers."
– Senior Scientist, Metabolic Disease Therapeutics Group
Associated Services
Based on the documented service portfolio, the glycan-related probiotic modification service engineers probiotic surfaces with specific carbohydrate structures for targeted therapeutic applications. The expertise in functionalizing biological surfaces with defined glycan motifs directly supports the scalable synthesis of precise carbohydrate antigens. We therefore extend this capability to our Carbohydrate Antigen Production Service, which includes the specialized synthesis of A-tetrasaccharide antigen, B-tetrasaccharide antigen, and A-trisaccharide antigen for immunology research and diagnostic development.
A-Tetrasaccharide Antigen
B-Tetrasaccharide Antigen
A-Trisaccharide Antigen
CD BioGlyco is the partner of choice for companies looking to lead the next wave of microbiome innovation. Contact us to learn more about our service that provides the biological precision required to turn probiotics into powerful, targeted therapeutic tools.
Reference
McDonald, A.G.; Lisacek, F. Simulated digestions of free oligosaccharides and mucin-type O-glycans reveal a potential role for Clostridium perfringens. Scientific Reports. 2024, 14(1): 1649. (Open Access)
For research use only. Not intended for any clinical use.
